These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
3. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE; Kleijnen J Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [TBL] [Abstract][Full Text] [Related]
4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]
5. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E; Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066 [TBL] [Abstract][Full Text] [Related]
7. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection. Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices. Shephard MD; Mazzachi BC; Watkinson L; Shephard AK; Laurence C; Gialamas A; Bubner T Rural Remote Health; 2009; 9(3):1189. PubMed ID: 19689171 [TBL] [Abstract][Full Text] [Related]
9. In vivo erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Hayashi M; MacGregor JT; Gatehouse DG; Blakey DH; Dertinger SD; Abramsson-Zetterberg L; Krishna G; Morita T; Russo A; Asano N; Suzuki H; Ohyama W; Gibson D; Mutat Res; 2007 Feb; 627(1):10-30. PubMed ID: 17157053 [TBL] [Abstract][Full Text] [Related]
11. Undertaking positive control studies as part of developmental neurotoxicity testing: a report from the ILSI Research Foundation/Risk Science Institute expert working group on neurodevelopmental endpoints. Crofton KM; Foss JA; Hass U; Jensen KF; Levin ED; Parker SP Neurotoxicol Teratol; 2008; 30(4):266-87. PubMed ID: 17681747 [TBL] [Abstract][Full Text] [Related]
12. A qualitative retrospective analysis of positive control data in developmental neurotoxicity studies. Crofton KM; Makris SL; Sette WF; Mendez E; Raffaele KC Neurotoxicol Teratol; 2004; 26(3):345-52. PubMed ID: 15113596 [TBL] [Abstract][Full Text] [Related]
13. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Korff S; Harvey BH Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714 [TBL] [Abstract][Full Text] [Related]
14. Regulatory developmental neurotoxicity and human risk assessment. Francis EZ Neurotoxicology; 1992; 13(1):77-84. PubMed ID: 1508435 [TBL] [Abstract][Full Text] [Related]
15. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675 [TBL] [Abstract][Full Text] [Related]
16. Alternative test methods in inhalation toxicology: challenges and opportunities. Costa DL Exp Toxicol Pathol; 2008 Jun; 60(2-3):105-9. PubMed ID: 18486462 [TBL] [Abstract][Full Text] [Related]
17. Strategy for genotoxicity testing--metabolic considerations. Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S; Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553 [TBL] [Abstract][Full Text] [Related]
18. Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directions. Ernst AA; Fish S Acad Emerg Med; 2005 Nov; 12(11):1050-5. PubMed ID: 16264073 [TBL] [Abstract][Full Text] [Related]
19. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology. Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955 [TBL] [Abstract][Full Text] [Related]
20. Behavioral methods in reproductive and developmental toxicology. Chester A; Hallesy D; Andrew F Neurobehav Toxicol Teratol; 1985; 7(6):745-52. PubMed ID: 3835476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]